As of 2024-12-13, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -13.01. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 491.62 mil USD. TBPH's TTM EBITDA according to its financial statements is -37.80 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.9x - 6.9x | 6.4x |
| Forward P/E multiples | 4.8x - 10.8x | 8.1x |
| Fair Price | (3.91) - (5.43) | (5.68) |
| Upside | -139.6% - -155.0% | -157.6% |
| Date | EV/EBITDA |
| 2024-12-06 | -13.02 |
| 2024-12-05 | -12.97 |
| 2024-12-04 | -12.64 |
| 2024-12-03 | -12.97 |
| 2024-12-02 | -12.45 |
| 2024-11-29 | -12.20 |
| 2024-11-27 | -12.42 |
| 2024-11-26 | -12.19 |
| 2024-11-25 | -12.49 |
| 2024-11-22 | -12.49 |
| 2024-11-21 | -12.67 |
| 2024-11-20 | -13.14 |
| 2024-11-19 | -13.07 |
| 2024-11-18 | -12.51 |
| 2024-11-15 | -12.55 |
| 2024-11-14 | -12.62 |
| 2024-11-13 | -12.76 |
| 2024-11-12 | -11.76 |
| 2024-11-11 | -11.98 |
| 2024-11-08 | -11.80 |
| 2024-11-07 | -11.55 |
| 2024-11-06 | -11.50 |
| 2024-11-05 | -10.93 |
| 2024-11-04 | -10.85 |
| 2024-11-01 | -10.94 |
| 2024-10-31 | -10.89 |
| 2024-10-30 | -11.19 |
| 2024-10-29 | -11.42 |
| 2024-10-28 | -11.58 |
| 2024-10-25 | -11.29 |
| 2024-10-24 | -11.41 |
| 2024-10-23 | -11.39 |
| 2024-10-22 | -11.61 |
| 2024-10-21 | -11.43 |
| 2024-10-18 | -11.61 |
| 2024-10-17 | -11.38 |
| 2024-10-16 | -11.48 |
| 2024-10-15 | -11.35 |
| 2024-10-14 | -10.87 |
| 2024-10-11 | -10.98 |
| 2024-10-10 | -10.65 |
| 2024-10-09 | -10.65 |
| 2024-10-08 | -10.48 |
| 2024-10-07 | -10.64 |
| 2024-10-04 | -10.70 |
| 2024-10-03 | -10.70 |
| 2024-10-02 | -10.85 |
| 2024-10-01 | -10.85 |
| 2024-09-30 | -10.65 |
| 2024-09-27 | -10.70 |